News

Streck Announces Series B Investment in Ceres Nanosciences

La Vista, Nebraska – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform.

“Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.”

Announcement_Graphics_FB_1200x630.jpg

This investment builds on the pre-existing partnership between Ceres and Streck, which has produced the Streck® Viral Extraction Kit, powered by Nanotrap technology, and a global distribution agreement covering Nanotrap particles for virus capture and concentration from wastewater samples.

“Ceres has a fantastic reputation for delivering innovative, high-quality products,” said Matthew Kreifels, Vice President of Sales. “We look forward to the positive impacts this partnership will have and working closely with their team to maximize the company’s impacts in the public health and diagnostics arenas.”

Streck will join Series A investor GreyBird Ventures on Ceres’ Board of Directors.

Read more here.

“We are very happy with our investment in Ceres and are pleased that Streck has joined us,” said Tom Miller, GreyBird Ventures Co-Founder and Chair of Ceres’ Board. “A world-class company like Streck as a strategic partner, coupled with a Ceres team that has demonstrated the ability to solve some of the most difficult problems in health care diagnostics, is a clear catalyst for accelerated growth.”

Recent News

09/16/2025

Lilly announces plans to build $5 billion manufacturing facility in Virginia

Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly’s emerging bioconjugate platform and monoclonal antibody portfolio. Earlier

09/09/2025

ATCC Receives Contract to Advance Industrial Biomanufacturing and Produce Synthetic Aviation Fuel Precursors

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been granted a contract with Capra Biosciences, a Virginia-based biotech company focused on the cost-competitive production of petrochemical replacements using its modular bioreactor platform. ATCC is supporting a contract with Capra to work on the Defense Advanced Research Projects Agency’s

09/05/2025

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system

RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) Direct to Phase II (R44) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop an ultrasound guidance solution for pediatric lumbar punctures (LPs) on its Accuro® 3S platform. Lumbar punctures